Building on the success of Bristol-Myers Squibb / Ono Pharmaceutical’s PD-1 inhibitor Opdivo in the recurrent renal cell carcinoma setting, combination regimens that include immune checkpoint inhibitors (e.g., Opdivo plus Yervoy) look set to revolutionize the treatment of advanced disease. Angiogenesis inhibitors remain a key feature in treatment, as Exelixis /Ipsen’s Cabometyx joins Pfizer’s Sutent and Novartis’s Votrient as a first-line treatment. The entry and increased market share of Cabometyx and Opdivo in this setting are beginning to shift Pfizer’s Inlyta, the combination of Eisai’s Lenvima / Kisplyx with Novartis’s Afinitor, and single-agent mTOR inhibitors to later lines. Furthermore, following Sutent’s FDA approval for high-risk early-stage (stage I-III) disease, multiple immune checkpoint inhibitors are anticipated to transition into early-stage treatments. As the highly competitive renal cell carcinoma market becomes increasingly fragmented, the developer of an efficacious and tolerable therapy could reap substantial commercial rewards.

Questions Answered:

  • How large are the early-stage and advanced or metastatic drug-treatable populations? Will drug-treatment rates change over time?
  • How is renal cell carcinoma currently treated, and what are interviewed experts’ insights on current treatment options? What clinical needs remain unfulfilled?
  • Who are the key players developing combination therapies for renal cell carcinoma? How will these combination regimens be differentiated, and which look the most promising?
  • Which emerging therapies do we forecast to enter each renal cell carcinoma setting? What uptake and sales will these therapies secure?

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: Twenty country-specific interviews with thought leaders (medical oncologists and urologists).

Key companies: Bristol-Myers Squibb/Ono Pharmaceutical, Merck & Co./MSD, Exelixis/Ipsen, and Pfizer.

Key drugs: Opdivo, Keytruda, Cabometyx, and Inlyta.

Population segments in market forecast: Early-stage (stage I-III) renal cell carcinoma, first-line advanced or metastatic renal cell carcinoma, second-line advanced or metastatic renal cell carcinoma, third-line advanced or metastatic renal cell carcinoma, and fourth-line advanced or metastatic renal cell carcinoma.

Emerging therapies: Phase III: 8 drugs; Phase II: 18 drugs; coverage of select Phase I and preclinical products.

Table of contents

  • Disease Landscape & Forecast
    • Key Findings
    • Key Updates
      • March 2020
      • December 2019
      • July 2019
      • May 2019
      • March 2019
      • December 2018
      • October 2018
    • Market Outlook
      • Key Findings
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Renal Cell Carcinoma?
        • What Factors Are Constraining the Market for Renal Cell Carcinoma?
      • Segment-Specific Trends
        • Early-Stage (Stage I-III) Renal Cell Carcinoma
        • First-Line Advanced or Metastatic Renal Cell Carcinoma
        • Second- and Later-Line Advanced or Metastatic Renal Cell Carcinoma
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
        • Disease Pathophysiology
        • Staging and Classification
        • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Incident Cases
        • Stage Distribution of Renal Cell Carcinoma
        • Recurrent Incident Cases of Renal Cell Carcinoma
        • Drug-Treatable Populations
        • Drug-Treated Populations
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Immune Checkpoint Inhibitors
        • Angiogenesis Inhibitors
        • mTOR Inhibitors
      • Medical Practice
        • Early-Stage Renal Cell Carcinoma: Stages I-III
        • First-Line Advanced or Metastatic Renal Cell Carcinoma: Stage IV
        • Second-Line Advanced or Metastatic Renal Cell Carcinoma
        • Third- and Fourth-Line Advanced or Metastatic Renal Cell Carcinoma
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Renal Cell Carcinoma
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Immune Checkpoint Inhibitors
        • Angiogenesis Inhibitors
        • Cytokines
        • Histone Deacetylase Inhibitors
        • Hypoxia-Inducible Factor (HIF)-2-Alpha Inhibitors
      • Early-Phase Pipeline Analysis
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug- and Regimen-Specific Assumptions
      • Bottom-Up Forecasting Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Cycles of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Renal Cell Carcinoma Bibliography

Author(s): Priyanka Mehra, B.Tech; Sorcha Cassidy M.Res., Ph.D

Priyanka Mehra is a Business Insights Analyst in the oncology team at Decision Resources Group. She has 5+ years of work experience in pharmaceutical research and analytics, involving management and execution of various strategic analysis projects across multiple oncology indications, secondary and primary research and competitive intelligence. Previously, she worked as an Associate Consultant with Prescient Healthcare Group where she handled Biosimilars projects for global pharmaceutical clients and designed brand and commercial strategy solutions on a variety of therapy areas, including oncology, immunology and inflammatory diseases. Prior to Prescient, she worked as a Senior Analyst with Smart Analyst where she worked on indication prioritization and clinical landscapes for major oncology indications such as NHL, NSCLC and CRC. She has also worked as a Senior Analyst with BioXcel Corporation where she was involved with projects on clinical trials and pipeline analysis, performance benchmarking, scouting and product profiling.

Sorcha Cassidy , is an Associate Director in the Oncology team at Decision Resources ; Dr. Cassidy manages a team of analysts who conduct extensive primary and secondary market research on several Oncology indications across the major pharmaceutical markets. She also provides sales and client support across all oncology products. She has in-depth expertise in competitive intelligence, secondary and primary market research, and delivering strategic insights that address key client business questions. Dr. Cassidy holds an and in Immunology from Imperial College London where she investigated the role of innate immune modulators (killer immunoglobulin-like receptors [KIR) on natural killer (NK) cells in various diseases and published several peer-reviewed papers. Prior to joining the company, Dr. Cassidy previously worked as a Market Research Manager in Janssen UK and has extensive experience working across multiple Oncology indications at GlobalData and FirstWord Pharma.


Related Reports

Renal Cell Carcinoma | Epidemiology | Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key renal cell carcinoma ...

View Details

Renal Cell Carcinoma | Epidemiology | Epidemiology Dashboard

DRG Epidemiology’s coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalenc...

View Details

Renal Cell Carcinoma | Current Treatment | Detailed, Expanded Analysis (US)

Market O

View Details

Renal Cell Carcinoma | Current Treatment | Detailed, Expanded Analysis: Treatment Sequencing (US)

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into...

View Details